Pacific Biosciences
PACB
210 hedge funds and large institutions have $4.42B invested in Pacific Biosciences in 2020 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 68 increasing their positions, 54 reducing their positions, and 35 closing their positions.
205% more capital invested
Capital invested by funds: $1.45B → $4.42B (+$2.97B)
106% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 35
26% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 54
21% more funds holding
Funds holding: 174 → 210 (+36)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
6.85% more ownership
Funds ownership: 84.13% → 90.98% (+6.9%)
2% more call options, than puts
Call options by funds: $41M | Put options by funds: $40.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$229M |
| 2 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
+$156M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$147M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$67.1M |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$36.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$50.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.6M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$37.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$33.4M |
| 5 |
Blackstone Inc
New York
|
-$23.8M |
PACB Hedge Fund Activity: Q4 2020 in Review
210 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2020, worth a combined $4.42B — up 205% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new PACB positions and 35 closed out — a net gain of 37 holders — while 68 added to existing stakes and 54 trimmed.
The largest buyer was Jackson Square Partners, opening a new position worth an estimated $229M. The largest seller was Viking Global Investors, cutting an estimated $50.2M.
- 210 institutional investors held Pacific Biosciences (PACB) as of Q4 2020, up from 174 in Q3 2020.
- Funds reported $4.42B of Pacific Biosciences stock for Q4 2020, up 205% quarter-over-quarter.
- 72 funds opened new Pacific Biosciences positions in Q4 2020 and 35 closed out, a net change of +37 holders.
- The largest Pacific Biosciences buyer in Q4 2020 was Jackson Square Partners, an estimated $229M added.
- The largest Pacific Biosciences seller in Q4 2020 was Viking Global Investors, an estimated $50.2M sold.
Based on aggregated 13F filings for Q4 2020.